Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 5/20 | 0.63 |
| ▸ | CA1 | P00915 | 5/20 | 0.63 |
| ▸ | CA2 | P00918 | 5/20 | 0.63 |
| ▸ | CA7 | P43166 | 5/20 | 0.63 |
| ▸ | CA9 | Q16790 | 5/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.54 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29220172 | 0.88 | CYP3A4 (0.66) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL2966217 | 0.87 | CA12 (0.63) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL15671718 | 0.85 | CYP3A4 (0.57) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL788648 | 0.84 | CYP3A4 (0.63) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL9127373 | 0.84 | CYP3A4 (0.56) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL9124680 | 0.84 | CYP3A4 (0.56) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL8106325 | 0.84 | GAA (0.57) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL7647241 | 0.84 | CYP3A4 (0.56) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL11267007 | 0.83 | CYP3A4 (0.54) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL10693946 | 0.83 | CYP3A4 (0.54) | SERPINE1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4217602-A | — | — | None | — | — | JP | disclosed |
| EP-3590940-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2021-06-09 | — | — | EP | disclosed |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10669268-B2 | Bicyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| CN-110526843-A | Inhibit calcium/calmodulin dependent protein kinase II compound and its application | ACADEMIA SINICA | 2019-12-03 | — | — | CN | disclosed |
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| CN-105268100-B | Nerve modulation apparatus and method | 安特罗麦迪克斯公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-106999543-A | Ophthalmic compositions comprising cyclosporine and trehalose | 汇恩斯株式会社 | 2017-08-01 | — | — | CN | disclosed |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-23 | — | — | US | disclosed |
| US-20070004726-A1 | Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2007-01-04 | — | — | US | disclosed |
| EP-1692572-A2 | ALKALINE, POST PLASMA ETCH/ASH RESIDUE REMOVERS AND PHOTORESIST STRIPPING COMPOSITIONS CONTAINING METAL-HALIDE CORROSION INHIBITORS | Mallinckrodt Baker, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005043245-A2 | ALKALINE, POST PLASMA ETCH/ASH RESIDUE REMOVERS AND PHOTORESIST STRIPPING COMPOSITIONS CONTAINING METAL-HALIDE CORROSION INHIBITORS | MALLINCKRODT BAKER INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-5688817-A | SKIN DISORDERS, ANTIINFLAMMATORY AGENTS, IMMUNOLOGY AND RHEUMATIC DISORDERS | CENTRE INT'L. DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1997-11-18 | — | — | US | disclosed |
| US-5668156-A | TREATMENT OF WARTS, ACNE, PSORIASIS, CORNEOPATHIES, KETONES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1997-09-16 | — | — | US | disclosed |
| US-5597839-A | TREATMENT OF SKIN DISORDERS OR ANTIINFLAMMATORY AGENTS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1997-01-28 | — | — | US | disclosed |
| US-5567721-A | AROMATIC UREA COMPOUND FOR SKIN DISORDER, RHEUMATIC DISEASE, RESPIRATORY DISORDER AND EYE DISORDER | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 1996-10-22 | — | — | US | disclosed |
| US-5439925-A | Skin disorders, rheumatic diseases | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-08-08 | — | — | US | disclosed |
| US-5387594-A | Administering for topical and systemic treatment of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-02-07 | — | — | US | disclosed |
| JP-H04217602-A | NEMATICIDE | TAKASAGO INTERNATL CORP | 1992-08-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669268-B2 | Bicyclic derivatives | CCNY, BICRA, UQCRB | SERPINE1 4702/4885CA12 3175/4885CA1 3286/4885 |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | SERPINE1 4762/4885CA12 3299/4885CA1 3541/4885 |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | SERPINE1 4762/4885CA12 3299/4885CA1 3541/4885 |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | CCNY, BICRA, UQCRB | SERPINE1 4702/4885CA12 3175/4885CA1 3286/4885 |
| US-20070004726-A1 | Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors | RARA, RARG, RARB | SERPINE1 2871/4885CA12 3791/4885CA1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.